Mercedes A García1, Graciela S Alarcón1, Gabriela Boggio1, Leticia Hachuel1, Ana Inés Marcos1, Juan Carlos Marcos1, Silvana Gentiletti1, Francisco Caeiro1, Emilia I Sato1, Eduardo F Borba1, João C Tavares Brenol1, Loreto Massardo1, José Fernando Molina-Restrepo1, Gloria Vásquez1, Marlene Guibert-Toledano1, Leonor Barile-Fabris1, Mary-Carmen Amigo1, Guillermo F Huerta-Yáñez1, Jorge M Cucho-Venegas1, Rosa Chacón-Diaz1, Bernardo A Pons-Estel2. 1. Reumatología, Hospital Interzonal General de Agudos General San Martín, La Plata, Argentina, Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, Departamento de Estadística, Universidad Nacional de Rosario, Reumatología, Hospital Provincial de Rosario, Rosario, Reumatología, Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Departmento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, Reumatología, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Reumatología, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, Reumatología, Universidad CES, Reumatología, Universidad de Antioquia, Hospital Universitario, Fundación San Vicente, Medellin, Colombia, Reumatología, Centro de Investigaciones Médico Quirúrgicas, Habana, Cuba, Reumatología, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico Distrito Federal, Reumatología, Centro Médico ABC, Ciudad de Mexico, Reumatología, Hospital Miguel Hidalgo, Aguascalientes, Mexico, Reumatología, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru and Reumatología, Hospital Universitario de Caracas, Venezuela. 2. Reumatología, Hospital Interzonal General de Agudos General San Martín, La Plata, Argentina, Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, Departamento de Estadística, Universidad Nacional de Rosario, Reumatología, Hospital Provincial de Rosario, Rosario, Reumatología, Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Departmento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, Reumatología, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Reumatología, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, Reumatología, Universidad CES, Reumatología, Universidad de Antioquia, Hospital Universitario, Fundación San Vicente, Medellin, Colombia, Reumatología, Centro de Investigaciones Médico Quirúrgicas, Habana, Cuba, Reumatología, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico Distrito Federal, Reumatología, Centro Médico ABC, Ciudad de Mexico, Reumatología, Hospital Miguel Hidalgo, Aguascalientes, Mexico, Reumatología, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru and Reumatología, Hospital Universitario de Caracas, Venezuela. baponsestel@buenaventuraguarani.com.ar.
Abstract
OBJECTIVES: The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLE patients (disease duration ≤2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries). METHODS: Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated. RESULTS: Of 1437 patients, 202 (14.1%) developed one or more manifestations: 164 pericarditis, 35 valvulopathy, 23 arrhythmias, 7 myocarditis and 1 endocarditis at follow-up; 77 of these patients also had an episode of primary cardiac disease at or before recruitment. In the multivariable parsimonious model, African/Latin American ethnicity [odds ratio (OR) 1.80, 95% CI 1.13, 2.86], primary cardiac disease at or before recruitment (OR 6.56, 95% CI 4.56, 9.43) and first SLICC/ACR Damage Index for SLE assessment (OR 1.31, 95% CI 1.14, 1.50) were risk factors for the subsequent occurrence of primary cardiac disease. CNS involvement (OR 0.44, 95% CI 0.25, 0.75) and antimalarial treatment (OR 0.62, 95% CI 0.44, 0.89) at or before recruitment were negatively associated with the occurrence of primary cardiac disease risk. Primary cardiac disease was not independently associated with mortality. CONCLUSION: Primary cardiac disease occurred in 14.1% of SLE patients of the Grupo Latino Americano de Estudio de Lupus cohort and pericarditis was its most frequent manifestation. African origin and lupus damage were found to be risk factors, while CNS involvement at or before recruitment and antimalarial treatment were protective. Primary cardiac disease had no impact on mortality.
OBJECTIVES: The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLEpatients (disease duration ≤2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries). METHODS: Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated. RESULTS: Of 1437 patients, 202 (14.1%) developed one or more manifestations: 164 pericarditis, 35 valvulopathy, 23 arrhythmias, 7 myocarditis and 1 endocarditis at follow-up; 77 of these patients also had an episode of primary cardiac disease at or before recruitment. In the multivariable parsimonious model, African/Latin American ethnicity [odds ratio (OR) 1.80, 95% CI 1.13, 2.86], primary cardiac disease at or before recruitment (OR 6.56, 95% CI 4.56, 9.43) and first SLICC/ACR Damage Index for SLE assessment (OR 1.31, 95% CI 1.14, 1.50) were risk factors for the subsequent occurrence of primary cardiac disease. CNS involvement (OR 0.44, 95% CI 0.25, 0.75) and antimalarial treatment (OR 0.62, 95% CI 0.44, 0.89) at or before recruitment were negatively associated with the occurrence of primary cardiac disease risk. Primary cardiac disease was not independently associated with mortality. CONCLUSION:Primary cardiac disease occurred in 14.1% of SLEpatients of the Grupo Latino Americano de Estudio de Lupus cohort and pericarditis was its most frequent manifestation. African origin and lupus damage were found to be risk factors, while CNS involvement at or before recruitment and antimalarial treatment were protective. Primary cardiac disease had no impact on mortality.
Authors: Piotr Bienias; Michał Ciurzyński; Bartłomiej Kisiel; Anna Chrzanowska; Katarzyna Ciesielska; Maria Siwicka; Agnieszka Kalińska-Bienias; Marek Saracyn; Monika Lisicka; Joanna Radochońska; Piotr Pruszczyk Journal: Rheumatol Int Date: 2018-11-12 Impact factor: 2.631
Authors: Juan Camilo Santacruz; Marta Juliana Mantilla; Igor Rueda; Gustavo Rodríguez-Salas; Sandra Pulido; John Londono Journal: Cureus Date: 2022-07-09
Authors: Ashira Blazer; Binhuan Wang; Danny Simpson; Tomas Kirchhoff; Sean Heffron; Robert M Clancy; Adriana Heguy; Karina Ray; Matija Snuderl; Jill P Buyon Journal: PLoS One Date: 2017-08-29 Impact factor: 3.240
Authors: Bernardo A Pons-Estel; Eloisa Bonfa; Enrique R Soriano; Mario H Cardiel; Ariel Izcovich; Federico Popoff; Juan M Criniti; Gloria Vásquez; Loreto Massardo; Margarita Duarte; Leonor A Barile-Fabris; Mercedes A García; Mary-Carmen Amigo; Graciela Espada; Luis J Catoggio; Emilia Inoue Sato; Roger A Levy; Eduardo M Acevedo Vásquez; Rosa Chacón-Díaz; Claudio M Galarza-Maldonado; Antonio J Iglesias Gamarra; José Fernando Molina; Oscar Neira; Clóvis A Silva; Andrea Vargas Peña; José A Gómez-Puerta; Marina Scolnik; Guillermo J Pons-Estel; Michelle R Ugolini-Lopes; Verónica Savio; Cristina Drenkard; Alejandro J Alvarellos; Manuel F Ugarte-Gil; Alejandra Babini; André Cavalcanti; Fernanda Athayde Cardoso Linhares; Maria Jezabel Haye Salinas; Yurilis J Fuentes-Silva; Ana Carolina Montandon de Oliveira E Silva; Ruth M Eraso Garnica; Sebastián Herrera Uribe; Diana Gómez-Martín; Ricardo Robaina Sevrini; Rosana M Quintana; Sergio Gordon; Hilda Fragoso-Loyo; Violeta Rosario; Verónica Saurit; Simone Appenzeller; Edgard Torres Dos Reis Neto; Jorge Cieza; Luis A González Naranjo; Yelitza C González Bello; María Victoria Collado; Judith Sarano; Soledad Retamozo; María E Sattler; Rocio V Gamboa-Cárdenas; Ernesto Cairoli; Silvana M Conti; Luis M Amezcua-Guerra; Luis H Silveira; Eduardo F Borba; Mariana A Pera; Paula B Alba Moreyra; Valeria Arturi; Guillermo A Berbotto; Cristian Gerling; Carla A Gobbi; Viviana L Gervasoni; Hugo R Scherbarth; João C Tavares Brenol; Fernando Cavalcanti; Lilian T Lavras Costallat; Nilzio A Da Silva; Odirlei A Monticielo; Luciana Parente Costa Seguro; Ricardo M Xavier; Carolina Llanos; Rubén A Montúfar Guardado; Ignacio Garcia de la Torre; Carlos Pineda; Margarita Portela Hernández; Alvaro Danza; Marlene Guibert-Toledano; Gil Llerena Reyes; Maria Isabel Acosta Colman; Alicia M Aquino; Claudia S Mora-Trujillo; Roberto Muñoz-Louis; Ignacio García Valladares; María Celeste Orozco; Paula I Burgos; Graciela V Betancur; Graciela S Alarcón Journal: Ann Rheum Dis Date: 2018-07-25 Impact factor: 19.103
Authors: Georgi Fram; Dee D Wang; Kelly Malette; Pedro Villablanca; Guson Kang; Kent So; Mir B Basir; Arfaat Khan; John E McKinnon; Marcus Zervos; William W O'Neill Journal: Curr Cardiol Rev Date: 2021